Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | CASR | P41180 | 10/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076516 | 0.81 | CCR5 (0.41) | ESR1ESR2KDM1ACASRDPP4 | |
| SCHEMBL1095801 | 0.78 | SSTR4 (0.39) | CYP2D6TACR1 | |
| SCHEMBL16274995 | 0.77 | SSTR4 (0.42) | CYP2D6 | |
| SCHEMBL1096488 | 0.77 | CCR5 (0.39) | ESR1ESR2KDM1ACASRCCR5 | |
| SCHEMBL1096263 | 0.77 | SSTR4 (0.39) | CYP2D6 | |
| SCHEMBL4106033 | 0.76 | CCR5 (0.40) | KDM1ACASRCCR5CYP2D6RORC | |
| SCHEMBL1095794 | 0.74 | CASR (0.45) | KDM1ACASR | |
| SCHEMBL1095736 | 0.73 | CASR (0.45) | KDM1ACASR | |
| Hydrochloric Acid SCHEMBL1096824 | 0.72 | CASR (0.45) | KDM1ACASR | |
| SCHEMBL3573558 | 0.71 | DPP4 (0.40) | CASRDPP4DPP7RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | ESR1 1384/4885ESR2 1866/4885KDM1A 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.